We operate a free-to-view policy, asking only that you register in order to read all of our content. Please login or register to view the rest of this article.
ARTICLE · 13 APRIL 2011
Working Example No Longer Required to Patent Monoclonal Antibodies
Norton Rose Fulbright Canada LLP
On June 4, 2010, the Patent Appeal Board ("Board") determined that claims to a monoclonalantibody are enabled where the antigen is a novel polypeptide which has been fully characterized (for example by complete amino acid sequence).
CanadaIntellectual Property






